The deal, expected to close in the second half of 2026, comes as Kenvue’s Tylenol political fight is heating up.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Scale for scale’s sake appears to have become passé, with conglomerates jockeying for market share with a more focused brand identity.